The UMT School of Pharmacy signed an MOU with Tigermed on 2nd March 2023. The MOU will allow SPH to develop collaborations in education and research and will facilitate
the provision of CGP (Clinical Good Practices) certifications to SPH faculty and students. Tigermed is a global clinical research organization operating in 54 countries. As a leading clinical Contract Research Organization (CRO), Tigermed fully participated
and supported the multicenter phase III clinical study of the Cansino Covid 19 vaccine and was responsible for cross-country coordination and operations, including project management, data management, biometrics, pharmacovigilance, third-party audit, etc. This was also the first China-initiated phase III vaccine clinical study that covered multiple continents, including Asia, Europe and Latin America.
© Copyright UMT, 2015. All Rights reserved.